pulmonary hypertension due to left heart disease
Conditions
Interventions
a Rho-kinase inhibitor is administered over a period of 30 minutes during cardiac catheterization
no administration of Rho-kinase inhibitor
Sponsors
LDH-PH study Project Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: pulmonary hypertension due to left heart disease with NYHA classification 2-4
Exclusion criteria
Exclusion criteria: 1) patients with severe primary valvular heart disease 2) patients with acute coronary syndrome 3) patients with carcinogenic shock 4) patients receiving mechanical ventilation 5) patients with pulmonary arterial hypertension and pulmonary hypertension due to lung disease and hypoxemia 6) patients with connective tissue disease 7) patients with chronic kidney disease stage 5 8) patients with pneumonia 9) patients of life expectancy is less than one year for the malignant tumor, etc 10) patients that might be pregnant or pregnant 11) patients research investigator or research sharing physician has determined to be inappropriate as a research subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in pulmonary vascular resistance after 30 minutes infusion of Rho-kinase inhibitor | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of cardiac index, mean pulmonary wedge pressure and cGMP after 30 minutes infusion of Rho-kinase inhibitor | — |
Countries
Japan
Contacts
Public ContactMasaki Ishiyama
Mie University Graduate School of Medicine Department of Cardiology and Nephrologyand Nephrology
Outcome results
None listed